Montelukast works by blocking the action of chemicals released by the body as part of allergic and inflammatory reactions
Scientists based in the US have devised a new way to make Montelukast, a drug used in the treatment of asthma and seasonal allergies.
Asthma is a chronic inflammatory disease of the airways which affects up to 300 million people worldwide and caused 250,000 deaths in 2011. Although there is no cure for asthma, symptoms can be managed through the use of fast-acting medication to treat acute attacks, and long-term control achieved using inhaled corticosteroids, sometimes in conjunction with a leukotriene antagonist, such as Montelukast.
Read the full article in Chemistry World»
Read the original journal article in Chemical Science – it’s free to access until 28th April:
Iron catalyzed enantioselective sulfa-Michael addition: a four-step synthesis of the anti-asthma agent Montelukast
James D. White and Subrata Shaw
Chem. Sci., 2014, DOI: 10.1039/C4SC00051J
